ClinicalTrials.gg
RecruitingNCT05552157DIAN-TUUpdated Nov 19, 2026

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

A Phase 2/3 interventional study of Remternetug (SC) and Matching Placebo (Remternetug) in Alzheimers Disease, Dementia and Alzheimers Disease, Familial, sponsored by Washington University School of Medicine. Recruiting at 37 sites in 15 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Washington University School of Medicine · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.
Updated Nov 19, 2026Site recruiting status changed2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Alzheimer Disease by Washington University School of Medicine — 8 open to participants now, 15 under way, 5 of them phase 3. Alzheimer Disease · Washington University School of Medicine.

Planned enrollment
5th of 14
280 · median 232
Started
2024
with 4 others
Phase 2/3
6 of 25
2 open now
Primary completion
2034-03
later than 13 of 14 live
Registered
15th of 25
by date

Among the 25 studies in Alzheimer Disease by Washington University School of Medicine, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is one of 5 that started in 2024, is one of 6 in phase 2/3, reaches primary completion later than 13 of the 14 other live ones, and was the 15th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 25 studies in Alzheimer Disease by Washington University School of Medicine are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Alzheimer Disease by Washington University School of Medicine, or all of them as a file.
02

Study summary

The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.

Read the detailed description

This study will recruit participants from the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS), a multicenter international study supported by the National Institutes of Health (Grant Number U01-AG032438; RJ Bateman), Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) sites, DIAN-TU partner sites, DIAN Expanded Registry (DIAN-EXR), and families identified by the sites. As part of the DIAN-TU-002 protocol, participants undergo longitudinal assessments that include clinical assessment, cognitive testing, magnetic resonance imaging (MRI) and amyloid imaging, and analysis of cerebrospinal fluid (CSF).

Participants in DIAN are recruited from families that have at least one member who has been identified as having a mutation linked to dominantly inherited Alzheimer's disease (DIAD). The mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor protein (APP) genes that are associated with DIAD have very high penetrance (near 100%). This study will enroll individuals who are either known to have a known disease-causing mutation, or who are at risk for such a mutation (the child or sibling of a proband with a known mutation) and unaware of their genetic status. Because the age at onset of cognitive changes is relatively consistent within each family and for each mutation, an age at onset is determined for each affected parent or mutation as part of the DIAN-OBS study protocol. This study will enroll participants who are asymptomatic and are within a specific window of time of expected age at onset for their family and/or mutation.

The ability to identify individuals destined to develop Alzheimer's disease (AD) with a high degree of confidence provides a unique opportunity to assess the efficacy of therapies at asymptomatic and very early stages of dementia. Families with known disease-causing mutations are extremely rare and are geographically dispersed throughout the world. These constraints necessitate a specialized study design. Participants in this study will not yet have developed any symptoms of AD; they will be "asymptomatic" carriers of mutations that cause DIAD and would be expected to perform normally on standard cognitive and functional testing. Further, most mutation carriers will have levels of AD-associated amyloid beta (Aβ) and non-Aβ biomarkers that are the same as non-carriers. Imaging and fluid biomarkers will be used to demonstrate that the treatment compounds have engaged their therapeutic targets. A set of cognitive measures designed to assess the very earliest and most subtle cognitive changes will be collected. However, the goal of this study is to address whether decreasing plaque prone Aβ peptides in the absence of measurable or mild elevations of Aβ plaques in participants with minimal to no amyloid plaque at baseline can lead to the subsequent prevention of non-Aβ biomarkers of disease progression. Additionally, because many at-risk individuals decide not to know whether they have the disease-associated mutation, some of the at-risk individuals enrolled in this study will not have the disease-causing mutations; they will be "mutation-negative." It is important to enroll these participants to avoid coercion (e.g., potential participants may feel pressured into genetic testing to learn their genetic status to be eligible for the trial). These mutation-negative individuals will be assigned to the placebo group and data will be used to determine normal ranges of outcome. Participants and site study staff will remain blinded as to these individuals' active or placebo group assignment and mutation status. Thus, the study will be blinded for placebo and for mutation status, except for mutation carriers who are aware of their genetic status. There may be exceptional circumstances as required by local regulation or health authorities where enrollment may be restricted to mutation carriers only, but such mandates will be thoroughly documented and agreed upon by the governing regulatory agency and the study sponsor.

This study is an adaptive-platform-based study. Several different therapies (each referred to as a study drug arm) may be tested in order to increase the likelihood that an effective treatment will be discovered. The compounds are selected for this trial based on mechanism of action and available data on efficacy and safety profile. In the case of multiple study arms, the study design includes a pooled placebo group (referred to as the mutation positive placebos) shared by all study drug arms. Mutation carriers will be assigned to a study drug arm and subsequently randomized within that arm in an overall 1:1 ratio to active drug: placebo. Mutation-negative participants will all receive placebo treatment. Participants and study staff will not be blinded as to which study drug arm each participant has been assigned; they will be blinded to whether participants have been randomized to receive active drug or placebo.

The study has 2 treatment periods: Stage 1 is a blinded placebo-controlled period that will continue until the last randomized participant completes 4 years of treatment (i.e., a common close design), and Stage 2 is an open-label period of 4 years (with a planned 2-year interim efficacy analysis) in which all mutation carriers will receive active drug. At the start of Stage 2, participants who were randomized to placebo in Stage 1 will follow the same dose titration schedule and MRI safety schedule used in Stage 1. Participants who were randomized to active drug in Stage 1 will follow a mock dose titration and will have the same MRI safety schedule used during the initial drug titration as Stage 1 but will remain on the dose that they were on at the end of Stage 1. This will protect the blind to the original treatment assignment from Stage 1. Participants, investigators, and the sponsor's clinical team will remain blinded throughout the study to the Stage 1 treatment assignment.

Stage 1 of the study is designed to test whether the study drug can slow, prevent, or reverse progression of Aβ pathology associated with AD and Stage 2 is designed to assess the study drug's effect on non-amyloid biomarkers of AD that may lead to future slowing or prevention of clinical symptoms of dementia.

Biomarker, cognitive, and/or clinical endpoints will be specified for each study drug arm. Biomarker data will be analyzed for pre-specified endpoints consistent with the drug's mechanism of action and other AD biomarker outcomes. The clinical and cognitive assessments are designed to assess subtle cognitive changes that may be detectable before the onset of dementia as well as cognitive and clinical decline in symptomatic groups.

Roche announced a decision to discontinue most of the company's global trials of gantenerumab. The DIAN-TU has paused the DIAN-TU-002 Primary Prevention Trial related to gantenerumab while considering other potential options for this platform trial.

The DIAN-TU has re-launched the DIAN-TU-002 Primary Prevention Trial with remternetug in collaboration with Eli Lilly and Company as part of this Master Protocol. The remternetug arm is posted under NCT06647498.

03

Conditions studied

  • Alzheimers Disease
  • Dementia
  • Alzheimers Disease, Familial

Keywords

  • Alzheimer's
  • Alzheimer's Disease
  • Dementia
  • Mutation
  • Genetic Mutation
  • Dominantly Inherited Alzheimer's Disease
  • Dominantly Inherited Alzheimer Network
  • Autosomal Dominant Alzheimer's Disease
  • Early Onset Alzheimer's Disease
  • DIAN
  • DIAN-TU
  • DIAN TU
  • DIAD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written , signed, and dated by the participant and study partner, or by the participant's legally authorized representative if applicable, according to local regulations for the ICF and, if applicable, country specific ICFs.
  2. Participant is at least 18 years old.
  3. People of

    1. Must have a negative serum pregnancy test at screening (V1)
    2. Must agree not to try to become pregnant from the time of signed ICF until twenty (20) weeks after the last dose of any study drug.
    3. Must agree not to breastfeed from the time of signed ICF until twenty (20) weeks after the last dose of any study drug.
    4. If partner is not sterilized, must agree to use highly effective measures, methods that can achieve a failure rate of less than 1% per year when used consistently and correctly from screening (V1) until twenty (20) weeks after last dose of any study drug.

    i. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal ii. progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable iii. intra-uterine device (IUD) iv. intrauterine hormone-releasing systems (IUS) v. bilateral tubal occlusion vi. vasectomized partner (only when this is the only partner) vii. true sexual abstinence when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods], declaration of abstinence for the duration of exposure to IMP, and withdrawal are not acceptable methods of contraception)

  4. Mutation Status:

    1. Participant is a carrier of a mutation in an APP, PSEN1, or PSEN2 gene that is associated with DIAD or does not know their mutation status and there is a mutation in their family pedigree that puts them at a direct risk of inheriting the known mutation;
    2. Participant is -25 to -11 years from predicted age of cognitive symptom onset based on their mutation type or family pedigree Note: If the at-risk parent is deemed a non-carrier through confirmed genetic testing at any time during the study, the participant will be withdrawn.
  5. Cognitive status of participant is normal (CDR-SB 0).
  6. Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning. Participants must be fluent in languages for which cognitive and clinical measures have been translated and validated for use in the DIAN-TU. Fluency is generally defined as daily or frequent functional use of a language generally from birth or a young age. In cultures where multiple languages are spoken or for participants who are multilingual, determination as to whether a participant's level of fluency in languages for which clinical and cognitive measures are available meets qualification for the study should be made by the site PI.
  7. Adequate visual and auditory abilities to perform all aspects of the cognitive and clinical assessments.
  8. Receiving stable doses of medication(s) for the treatment of non-excluded medical condition(s) for at least 30 days prior to baseline visit (V2) with the exceptions of medications taken for episodic conditions (e.g., migraine abortive therapy, antibiotics, and other medications for upper respiratory and gastrointestinal ailments).
  9. Has a study partner who in the PI's judgment can provide accurate information as to the participant's cognitive and functional abilities, who agrees to provide information at the study visits that require study partner input for scale completion, and who signs the necessary ICF, if applicable.
  10. Agrees not to donate blood or blood products for transfusion from the time of Screening (V1) for a study drug arm, for the duration of the study, and for 5 half lives after the final dose of study drug.
  11. In the opinion of the PI, the participant will be compliant and have a high probability of completing the study.
  12. Willing to complete all study-related testing, evaluations, and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Significant neurologic disease (other than AD) or psychiatric disease that may currently or during the study affect cognition or the participant's ability to complete the study. This would include disorders such as: recent or severe head trauma causing cognitive change, seizure disorder, neurodegenerative disease other than DIAD, hydrocephalus, cerebral/spinal hematoma, inflammatory disease, CNS infection (e.g., encephalitis or meningitis), neoplasm, toxic exposure, metabolic disorder (including hypoxic or hypoglycemic episodes) or endocrine disorder; psychiatric disorders such as schizophrenia, schizoaffective disorder, bipolar disorder or major depression, or any other psychiatric condition/disorder which could significantly interfere with the participant's cooperative participation (e.g., prominent anxiety, agitation or behavioral problems).

    Disorders that are controlled medically or remote history of these disorders (e.g., history of febrile seizures in childhood) that are not likely to interfere with cognitive function and compliance with study procedures are not exclusionary.

  2. At high risk for suicide, e.g., significant suicidal ideation or attempt within last 12 months, current major depression (as defined in , Fifth Edition [DSM-V]), or increased suicide risk based on screening Columbia Suicide Severity Rating Scale (C-SSRS). Current stable mild depression or current use of antidepressant medications are not exclusionary.
  3. History of clinically evident stroke or history of carotid or vertebrobasilar stenosis, plaque, or other prominent risk factor for stroke or cerebral hemorrhage (including atrial fibrillation and anticoagulation, documented [TIA] in the last 12 months) that may be interfering with cognition or is likely to impact with the participant's ability to complete the study.
  4. Alcohol or substance use sufficient to meet DSM-V criteria currently or within the past year.
  5. History of or Baseline (V2) visit brain MRI scan indicative of any other significant abnormality, definite microhemorrhages, evidence of a cerebral contusion, encephalomalacia, or aneurysms. Minor or clinically insignificant imaging findings are not exclusionary.
  6. Presence of certain implanted medical devices, such as some pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin, or body which would preclude MRI scan.
  7. Cardiovascular complications such as uncontrolled hypertension, history of myocardial infarcts, heart failure, atrial fibrillation, long on likely to interfere with participation in or analysis of the trial in the opinion of the investigator
  8. Hepatic or renal abnormalities that in the opinion of the investigator would interfere with participation in or analysis of the trial.
  9. History of (HIV) infection, history of infection within the past year, history of infection which has not been adequately treated, history of spirochete infection (e.g., syphilis, Lyme) of the CNS or history of other infection with high risk for interfering with participation or interpretation of the study in the opinion of the investigator.
  10. History of clinically significant multiple or severe drug allergies, significant atopy, or severe post-treatment reactions (including but not limited to erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis) or sensitivity to study-drug specific PET imaging agents with a high risk for interfering with participation or interpretation of the study in the opinion of the investigator.
  11. Treatment with medications (e.g., systemic ) within 90 days prior to Baseline (V2) visit (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for within the last 3 years.
  12. Current clinically significant abnormalities of thyroid function, or clinically significant deficiency in vitamin B12. Vitamin B12 less than the lower limits of normal with normal methylmalonic acid (MMA)/homocysteine is not deemed clinically significant, therefore not exclusionary.
  13. Unstable or poorly controlled diabetes which the investigator believes may interfere with participation in or analysis of the study protocol. Participants may be rescreened after 3 months to allow optimization of diabetic control
  14. Morbid obesity with significant comorbidities or that would preclude MRI imaging.
  15. Current use of anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, or apixaban). Daily use of low dose (\< 325 mg) aspirin is not exclusionary.
  16. Have been exposed to a monoclonal antibody targeting Aβ peptide within the past 6 months or 5 half-lives from screening, whichever is longer.
  17. Received any other pharmacological treatment within 3 months of Screening or 5 half-lives, whichever is longer.

    Note: Use of approved treatments for AD and other medications may be permitted in this study.

  18. Lack of sufficient venous access.
  19. Clinically relevant abnormalities in hematology, coagulation, or clinical chemistry.
  20. History of cancer that the investigator believes has high risk of recurrence and impacting study participation or analysis.
  21. Any other medical condition that could be expected to progress, recur, or change to such an extent that it could bias the assessment of the clinical or mental status of the participant to a significant degree or put the participant at special risk.
  22. Currently, or within the last month prior to screening, participated in a clinical study, including a nonpharmacological study, without prior approval.
  23. Participants with the "Dutch" APP E693Q mutation.
  24. Unable to complete baseline visit (V2) procedures with appropriate cognitive and clinical scores for eligibility
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Stage 1: Remternetug

    Active Remternetug- blinded

    Drug: Remternetug (SC)

  • Placebo comparator
    Stage 1: Matching Placebo (Remternetug)

    Matching placebo

    Drug: Matching Placebo (Remternetug)

  • Active comparator
    Stage 2: Remternetug Open Label

    Open label will start after last dose of Stage 1

    Drug: Remternetug (SC)

Interventions

  • DrugRemternetugStudies of RemternetugRemternetug pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered subcutaneously every 12 weeks

  • DrugMatching Placebo (Remternetug)

    Administered as subcutaneous injection of placebo every 12 weeks

06

What researchers measure

Primary outcomes

  1. Stage 1: Evaluate the ability of study drug to prevent or slow the rate of Aβ accumulation compared with placebo in participants with mutations that cause DIAD

    Defined in each drug-specific appendix; will be an assessment of biomarkers of early-stage disease (e.g., amyloid PET, soluble amyloid, soluble phospho-tau) compared with baseline in each treatment group

    Time frame: Baseline and Week 208

  2. Stage 2: Evaluate the effect of anti-amyloid treatment on downstream biomarkers of AD

    If applicable, will be defined in each drug-specific appendix, and will be an assessment of the change in progression of biomarkers representing tau, neurodegenerative, and inflammatory pathobiological events in the disease cascade for temporally different periods of the pre-symptomatic phases of the disease.

    Time frame: Stage 2 Week 208

07

Study locations

30 of 37 sites recruiting
  • University of Alabama in Birmingham
    Birmingham, Alabama 35294, United States
    Recruiting
    • Erik Roberson · Principal investigator
  • University of California San Diego Medical Center
    La Jolla, California 92037, United States
    Recruiting
    • Doug Galasko · Principal investigator
  • University of Southern Califonria
    Los Angeles, California 90089, United States
    Recruiting
    • John Ringman · Principal investigator
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
    Recruiting
    • Christopher Van Dyck · Principal investigator
  • Emory University
    Atlanta, Georgia 30329, United States
    Recruiting
    • James Lah · Principal investigator
  • Advocate Lutheran General Hospital
    Park Ridge, Illinois 60068, United States
    Recruiting
    • Darren Gitelman · Principal investigator
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Jared Brosch · Principal investigator
  • Washington University in St. Louis
    St Louis, Missouri 63110, United States
    Recruiting
    • Barbara Snider · Principal investigator
  • New York University Medical Center
    New York, New York 10016, United States
    Recruiting
    • Thomas Wisniewski · Principal investigator
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
    • Sarah Berman · Principal investigator
  • Butler Hospital
    Providence, Rhode Island 02096, United States
    Recruiting
    • Edward Denmead Huey · Principal investigator
  • Kerwin Research and Memory Center
    Dallas, Texas 75231, United States
    Recruiting
    • Alka Khera · Principal investigator
  • University of Washington
    Seattle, Washington 98195, United States
    Recruiting
    • Suman Jayadev · Principal investigator
  • Instituto de Investigaciones Neurologicas Raul Carrea, FLENI
    Ciudad Autonoma de Buenos Aire, C1428AQK, Argentina
    Recruiting
    • Ricardo Allegri · Principal investigator
  • Neuroscience Research Australia
    Randwick, New South Wales 2031, Australia
    Recruiting
    • Emma Devenney · Principal investigator
  • Alzheimer's Research Australia
    Melbourne, Victoria 3010, Australia
    Recruiting
    • Colin Masters · Principal investigator
  • UBC Hospital
    Vancouver, British Columbia V6T 2B5, Canada
    Recruiting
    • Robin Hsiung · Principal investigator
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
    • Mario Masellis · Principal investigator
  • McGill Center for Studies in Aging
    Verdun, Quebec H4H 1R3, Canada
    Recruiting
    • Paola Vitali · Principal investigator
  • CHU de Quebec - Hôpital de l' Enfant Jésus
    Québec, G1J 1Z4, Canada
    Recruiting
    • Robert LaForce · Principal investigator
  • Grupo de Neurociencias Sede de la Universidad de Antioquia
    Medellín, Colombia
    Recruiting
    • David Fernando Aguillon Nino, M.D. · Principal investigator
  • CHU de Toulouse - Hôpital Purpan
    Toulouse, Haute Garonne 31059, France
    Not yet recruiting
    • Jérémie Pariente · Principal investigator
  • Hopital Roger Salengro - CHU Lille
    Lille, Nord 59037, France
    Not yet recruiting
    • Adeline Rollin-Sillaire · Principal investigator
  • Groupe Hospitalier Pitie-Salpetriere
    Paris, Paris 69677, France
    Not yet recruiting
    • Nicolas Villian · Principal investigator
  • Hopital Neurologique Pierre Wertheimer
    Bron, Rhone 69677, France
    Not yet recruiting
    • Maité Formaglio · Principal investigator
  • CHU de Rouen - Hôpital Charles Nicolle
    Rouen, Seine Maritime 76031, France
    Recruiting
    • David Wallon · Principal investigator
  • Universitaetsklinikum Tubingen
    Tübingen, Baden-Wurttemberg 72076, Germany
    Recruiting
    • Cristoph Laske, M.D. · Principal investigator
  • LMU-Campus Grosshadern
    Munich, Bavaria 81377, Germany
    Recruiting
    • Johannes Levin, M.D, · Principal investigator
  • IRCCS Centro San Giovanni di Dio Fatebenefratelli
    Brescia, 25125, Italy
    Recruiting
    • Barbara Borroni · Principal investigator
  • Azienda Ospedaliera Universitaria Careggi
    Florence, 50134, Italy
    Recruiting
    • Valentina Bessi, M.D. · Principal investigator
  • Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
    Mexico City, Mexico City 14269, Mexico
    Not yet recruiting
    • Ana Luisa Sosa Ortiz, M.D. · Principal investigator
  • Brain Research Center
    Amsterdam, 1081 GM, Netherlands
    Not yet recruiting
    • Jort Vijverberg, MD · Principal investigator
  • New Zealand Brain Research Institute
    Christchurch, 8011, New Zealand
    Recruiting
    • Campbell Le Heron, M.D. · Principal investigator
  • University of Puerto Rico, School of Medicine
    San Juan, Puerto Rico 00936, Puerto Rico
    Recruiting
    • Ivonne Jimenez-Velazquez · Principal investigator
  • Asan Medical Center
    Seoul, South Korea
    Not yet recruiting
    • Jae Sung Lim · Principal investigator
  • Hospital Clínic I Provincial de Barcelona
    Barcelona, Barcelona 8036, Spain
    Recruiting
    • Raquel Sanchez Valle · Principal investigator
  • The National Hospital for Neurology and Neurosurgery
    London, Greater London WC1B 3BG, United Kingdom
    Recruiting
    • Catherine Mummery · Principal investigator
08

References and documents

Publications

  • McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14. PubMed 30217935 ↗
  • Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013 Oct;169(10):737-43. doi: 10.1016/j.neurol.2013.07.017. Epub 2013 Sep 6. PubMed 24016464 ↗
  • Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30;367(9):795-804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11. PubMed 22784036 ↗
  • Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, Pontecorvo MJ, Mintun MA, Devous MD Sr. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 2018 Dec;14(12):1565-1571. doi: 10.1016/j.jalz.2018.06.1353. Epub 2018 Jul 11. PubMed 30006100 ↗
  • Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron. 2012 Dec 6;76(5):908-20. doi: 10.1016/j.neuron.2012.10.029. PubMed 23217740 ↗
  • Young AL, Oxtoby NP, Daga P, Cash DM, Fox NC, Ourselin S, Schott JM, Alexander DC; Alzheimer's Disease Neuroimaging Initiative. A data-driven model of biomarker changes in sporadic Alzheimer's disease. Brain. 2014 Sep;137(Pt 9):2564-77. doi: 10.1093/brain/awu176. Epub 2014 Jul 9. PubMed 25012224 ↗
  • McDade E, Bateman RJ. Tau Positron Emission Tomography in Autosomal Dominant Alzheimer Disease: Small Windows, Big Picture. JAMA Neurol. 2018 May 1;75(5):536-538. doi: 10.1001/jamaneurol.2017.4026. No abstract available. PubMed 29435570 ↗
  • Wang G, Berry S, Xiong C, Hassenstab J, Quintana M, McDade EM, Delmar P, Vestrucci M, Sethuraman G, Bateman RJ; Dominantly Inherited Alzheimer Network Trials Unit. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Stat Med. 2018 Sep 20;37(21):3047-3055. doi: 10.1002/sim.7811. Epub 2018 May 14. PubMed 29761523 ↗
  • Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, Langbaum JB, Mills SL, Reiman EM, Sperling R, Santacruz AM, Tariot PN, Welsh-Bohmer KA. Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimers Dement. 2016 May;12(5):631-2. doi: 10.1016/j.jalz.2016.04.001. No abstract available. PubMed 27157073 ↗
  • Grill JD, Bateman RJ, Buckles V, Oliver A, Morris JC, Masters CL, Klunk WE, Ringman JM; Dominantly Inherited Alzheimer's Network. A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2015 Jul 22;7(1):50. doi: 10.1186/s13195-015-0135-0. eCollection 2015. PubMed 26203303 ↗
  • McDade E, Bateman RJ. Stop Alzheimer's before it starts. Nature. 2017 Jul 12;547(7662):153-155. doi: 10.1038/547153a. No abstract available. PubMed 28703214 ↗
  • Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014 Jul 15;83(3):253-60. doi: 10.1212/WNL.0000000000000596. Epub 2014 Jun 13. PubMed 24928124 ↗
  • Weng H, Bateman R, Morris JC, Xiong C. Validity and power of minimization algorithm in longitudinal analysis of clinical trials. Biostat Epidemiol. 2017;1(1):59-77. doi: 10.1080/24709360.2017.1331822. Epub 2017 Jun 13. PubMed 29250611 ↗

Individual participant data

Plan to share: Yes — Access to DIAN-TU trial data will follow the DIAN-TU data access policy, which complies with the guidelines established by the Collaboration for Alzheimer's Prevention [CAP REF].

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2034, 112 months after the start.

Of 28 phase 2/3 interventional studies under Alzheimer Disease, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 70. This study's planned 112 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2022
First posted
Sep 23, 2022
StartActual
Nov 22, 2024
Primary completionEst.
Mar 30, 2034
CompletionEst.
Aug 30, 2034
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • University of Southern Califonria · Los Angeles, United StatesNot yet recruiting→Recruiting
  • CHU de Rouen - Hôpital Charles Nicolle · Rouen, FranceNot yet recruiting→Recruiting
  • LMU-Campus Grosshadern · Munich, GermanyNot yet recruiting→Recruiting
  • IRCCS Centro San Giovanni di Dio Fatebenefratelli · Brescia, ItalyNot yet recruiting→Recruiting
  • Azienda Ospedaliera Universitaria Careggi · Florence, ItalyNot yet recruiting→Recruiting
  • New Zealand Brain Research Institute · Christchurch, New ZealandNot yet recruiting→Recruiting
Show 2 added (1 Puerto Rico, 1 Spain)
  • University of Puerto Rico, School of Medicine · San Juan, Puerto Rico
  • Hospital Clínic I Provincial de Barcelona · Barcelona, Spain
Show 2 removed
  • University of Puerto Rico, School of Medicine · San Juan, Puerto Rico
  • Hospital Clínic I Provincial de Barcelona · Barcelona, Spain
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    2 sites added, 2 sites removed. 6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • University of Southern Califonria · Los Angeles, United StatesNot yet recruiting→Recruiting
    • CHU de Rouen - Hôpital Charles Nicolle · Rouen, FranceNot yet recruiting→Recruiting
    • LMU-Campus Grosshadern · Munich, GermanyNot yet recruiting→Recruiting
    • IRCCS Centro San Giovanni di Dio Fatebenefratelli · Brescia, ItalyNot yet recruiting→Recruiting
    • Azienda Ospedaliera Universitaria Careggi · Florence, ItalyNot yet recruiting→Recruiting
    • New Zealand Brain Research Institute · Christchurch, New ZealandNot yet recruiting→Recruiting
    Show 2 added (1 Puerto Rico, 1 Spain)
    • University of Puerto Rico, School of Medicine · San Juan, Puerto Rico
    • Hospital Clínic I Provincial de Barcelona · Barcelona, Spain
    Show 2 removed
    • University of Puerto Rico, School of Medicine · San Juan, Puerto Rico
    • Hospital Clínic I Provincial de Barcelona · Barcelona, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05552157
Collaborators
Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA)
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Nov 22, 2024
Primary completion
Mar 30, 2034 (estimated)
Completion
Aug 30, 2034 (estimated)
Last update
Nov 19, 2026

Study contacts

Jamie Bartzel
Contact
dianexr@wustl.edu
844-DIANEXR (342-6397)
Ellen Ziegemeier
Contact
dianexr@wustl.edu
844-DIANEXR (342-6397)
Eric M McDade, DO
study director · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remternetug

Start the discussion